Equities Analysts Issue Forecasts for MNMD Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Mind Medicine (MindMed) to ($0.51) per share, down from a previous estimate of ($0.36).
• The company reported a Q2 EPS of ($0.50), which missed analyst expectations by ($0.12).
• Despite the negative outlook, seven analysts maintain a "buy" rating for Mind Medicine (MindMed) with an average price target of $24.71.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for shares of Mind Medicine (MindMed) in a report released on Monday, August 4th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their previous estimate of ($0.36). The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.04) EPS and FY2027 earnings at ($1.48) EPS.

Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Tuesday, May 13th. Oppenheimer began coverage on shares of Mind Medicine (MindMed) in a research report on Monday. They issued an "outperform" rating and a $25.00 price objective for the company. Finally, Chardan Capital restated a "buy" rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, August 1st. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $24.71.

Mind Medicine (MindMed) Stock Performance

Shares of NASDAQ MNMD traded up $0.10 during midday trading on Wednesday, reaching $9.99. 959,982 shares of the stock were exchanged, compared to its average volume of 1,290,042. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 0.22. The firm has a market cap of $754.77 million, a price-to-earnings ratio of -6.53 and a beta of 2.49. The firm has a 50-day simple moving average of $8.02 and a two-hundred day simple moving average of $7.19. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $10.44.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.12).

Hedge Funds Weigh In On Mind Medicine (MindMed)

Several hedge funds and other institutional investors have recently made changes to their positions in MNMD. Teacher Retirement System of Texas increased its position in shares of Mind Medicine (MindMed) by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company's stock worth $106,000 after purchasing an additional 1,400 shares in the last quarter. Palumbo Wealth Management LLC lifted its holdings in Mind Medicine (MindMed) by 6.3% in the 2nd quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company's stock valued at $156,000 after purchasing an additional 1,415 shares in the last quarter. Corebridge Financial Inc. boosted its stake in Mind Medicine (MindMed) by 4.1% during the 4th quarter. Corebridge Financial Inc. now owns 40,064 shares of the company's stock worth $279,000 after purchasing an additional 1,569 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Mind Medicine (MindMed) by 6.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,867 shares of the company's stock worth $169,000 after buying an additional 1,669 shares in the last quarter. Finally, CWM LLC raised its position in shares of Mind Medicine (MindMed) by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company's stock valued at $29,000 after buying an additional 1,796 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company's stock.

Insider Buying and Selling at Mind Medicine (MindMed)

In other news, insider Mark Sullivan sold 11,491 shares of the business's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total transaction of $78,138.80. Following the completion of the sale, the insider owned 305,130 shares of the company's stock, valued at $2,074,884. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert Barrow sold 26,491 shares of the company's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $6.80, for a total transaction of $180,138.80. Following the transaction, the chief executive officer owned 830,065 shares of the company's stock, valued at approximately $5,644,442. This trade represents a 3.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,830 shares of company stock valued at $311,644 over the last ninety days. Corporate insiders own 2.45% of the company's stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.